Pharmaceutical

Drug Farm candidate gains rare paediatric disease status  

Drug Farm’s ALPK1 inhibitor DF-003 is being investigated in a Phase I trial for the treatment of ROSAH, enrolling 96 healthy subjects.

Jan 15, 2024 - 18:00
Drug Farm candidate gains rare paediatric disease status  
Drug Farm’s ALPK1 inhibitor DF-003 is being investigated in a Phase I trial for the treatment of ROSAH, enrolling 96 healthy subjects.
Read the original article

Tags:

Previous Article

Opinion: What STAT readers think about JPM’s locked lactation room, covering wei...

Next Article

Amgen showcases exciting potential in the obesity space at JPM24

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Roche’s $3 billion Alnylam deal shows drug firms are interested in long-acting heart drugs

STAT+: Roche’s $3 billion Alnylam deal shows drug firms...

Jul 24, 2023

STAT+: ImmunoGen drug prolongs survival of women with advanced ovarian cancer

STAT+: ImmunoGen drug prolongs survival of women with a...

Jun 4, 2023

Race for a first-to-market therapy for NASH heats up

Race for a first-to-market therapy for NASH heats up

Mar 21, 2023